Enhance Skin Products Inc

CIK:0001395400|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2017	Jan. 31, 2016	Jan. 31, 2017	Jan. 31, 2016
Income Statement [Abstract]
SALES			$ 443	$ 235
EXPENSES
General and administrative	573	5,420	11,283	17,059
Legal and professional fees	40,530	129,384	373,646	284,701
Marketing				14,000
Total operating expenses	41,103	134,804	384,929	315,760
Gain on sale of assets (Note 5)	(2,696,105)		(2,696,105)
Day one impairment of investment in Integumen (Note 5)	2,179,832		2,179,832
Impairment of goodwill				2,499
Exchange (gain) loss	32		(5,457)
Loss due to settlement of related party payables	18,811		18,811
Interest expense		38,432	7,821	76,171
Net gain (loss) for the period before income taxes	456,327	(173,236)	110,612	(394,195)
Income taxes
Net gain (loss) for the period	456,327	(173,236)	110,612	(394,195)
Foreign currency translation adjustment	(301)	(18)	(1,139)	(891)
Comprehensive gain (loss)	$ 456,026	$ (173,254)	$ 109,473	$ (395,086)
Gain (loss) per share, basic and diluted	$ 0.0017	$ (0.0016)	$ 0.0007	$ (0.0038)
Weighted average number of common shares outstanding	265,804,851	108,598,645	165,236,314	104,115,035

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jan. 31, 2017	Jan. 31, 2016
OPERATING ACTIVITIES
Net gain (loss) for the period	$ 110,612	$ (394,195)
Beneficial conversion feature on advances from a related party	7,821	51,163
Gain of sale of assets	(2,696,105)
Day one impairment of investment in Integumen	2,179,832
Loss due to settlement of related party payables	18,811
Accretion expense on convertible promissory note		22,958
Impairment of goodwill		2,499
Net change in non-cash working capital balances:
Shares issued against consulting expenses	14,531	27,562
Accounts payable to related parties	65,741	47,730
Accounts payable from related parties convertible into shares	133,242	111,370
Accounts payable and accrued liabilities	(1,446)	34,463
Cash used in operating activities	(166,961)	(96,450)
FINANCING ACTIVITIES
Proceeds from issuance of secured promissory convertible note	100,000	43,000
Advances from related parties convertible into shares	11,035	57,080
Advances from Integumen for interim costs	55,000
Cash provided by financing activities	166,035	100,080
Net increase in cash during the period	(926)	3,630
Effect of foreign currency translation	(1,139)	(891)
Cash, beginning of the period	2,847	1,582
Cash, end of period	782	4,321
Supplemental disclosure with respect to cash flows:
Cash paid for income taxes
Cash paid for interest

Condensed Consolidated Balance Sheets - USD ($)	Jan. 31, 2017	Apr. 30, 2016
ASSETS
Cash	$ 782	$ 2,847
Due from Integumen Inc.	28,747
Total current assets	29,529	2,847
Investment in Integumen (Note 5)	1
Goodwill (Note 8)		1
Total assets	29,530	2,848
Liabilities
Accounts payable and accrued liabilities	57,457	271,635
Accounts payable to related parties (Note 4)	19,448	75,607
Accounts payable to related parties convertible into shares (Note 4)	46,998	248,600
Advances from a related party (Note 4)		96,489
Advances from related parties convertible into shares (Note 4)		305,540
Total current liabilities	123,903	997,871
Total liabilities	123,903	997,871
Stockholders' deficit
Authorized: 600,000,000 common shares par value $0.001 as of January 31, 2017 (April 30, 2016: 600,000,000 common shares) - (Note 6) Issued and outstanding 338,344,678 common shares as of January 31, 2017 (April 30, 2016: 113,951,705 common shares) - (Note 6)	338,345	113,951
Additional paid-in capital	2,538,331	1,971,548
Accumulated other comprehensive (loss) gain	7,670	8,809
Accumulated deficit	(2,978,719)	(3,089,331)
Total stockholders' deficit	(94,373)	(995,023)
Total liabilities and stockholders' deficit	$ 29,530	$ 2,848